KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $1.4 billion.

  • Resmed's Cash & Equivalents rose 17149.83% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year increase of 17149.83%. This contributed to the annual value of $1.2 billion for FY2025, which is 40740.26% up from last year.
  • Per Resmed's latest filing, its Cash & Equivalents stood at $1.4 billion for Q4 2025, which was up 17149.83% from $1.4 billion recorded in Q3 2025.
  • Over the past 5 years, Resmed's Cash & Equivalents peaked at $1.4 billion during Q4 2025, and registered a low of $194.5 million during Q4 2021.
  • Its 5-year average for Cash & Equivalents is $458.8 million, with a median of $245.8 million in 2022.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 3624.65% in 2021, then surged by 40740.26% in 2025.
  • Resmed's Cash & Equivalents (Quarter) stood at $194.5 million in 2021, then skyrocketed by 30.2% to $253.2 million in 2022, then fell by 16.96% to $210.2 million in 2023, then soared by 148.25% to $521.9 million in 2024, then surged by 171.5% to $1.4 billion in 2025.
  • Its Cash & Equivalents stands at $1.4 billion for Q4 2025, versus $1.4 billion for Q3 2025 and $1.2 billion for Q2 2025.